Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļALKS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAlkermes Plc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 16, 1991
āļāļĩāļāļĩāđāļPops (Richard F)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ1800
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 16
āļāļĩāđāļāļĒāļđāđConnaught House
āđāļĄāļ·āļāļDUBLIN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻIreland
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđD04 C5Y6
āđāļāļĢāļĻāļąāļāļāđ35317728000
āđāļ§āđāļāđāļāļāđhttps://www.alkermes.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļALKS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 16, 1991
āļāļĩāļāļĩāđāļPops (Richard F)
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Mr. Shane M. Cooke
Independent Director
Mr. Shane M. Cooke
Independent Director
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
Mr. Brian P. McKeon
Independent Director
Mr. Brian P. McKeon
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Mr. Shane M. Cooke
Independent Director
Mr. Shane M. Cooke
Independent Director